← Drug database

Zoledronic acid Teva Generics (zoledronic acid)

Generic
Region
🇪🇺 EU
Active substance
zoledronic acid
Company
Teva Generics B.V
Status
Withdrawn
Therapeutic area
Osteoporosis; Osteitis Deformans
CHMP opinion
Thu 23 Jan 2014
EU approval
Thu 27 Mar 2014
Designations
Generic
Application
EMEA/H/C/002805
ATC
M05BA08
Official record
www.ema.europa.eu

Indication

Treatment of osteoporosis in post-menopausal women in adult men at increased risk of fracture, including those with recent low-trauma hip fracture. Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women in adult men at increased risk of fracture. Treatment of Paget's disease of the bone in adults.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

Follow Zoledronic acid Teva Generics

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.